Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Applying to Barnes-Jewish Hospital - Siteman Cancer Center (Washington University - St. Louis) · St Louis, Missouri
Answer a few short questions to share with the research team.